title: Treatment of feline diabetes mellitus using an alpha-glucosidase inhibitor and a low-carbohydrate diet.
abstract: The purpose of this study was to determine the effect of an alpha-glucosidase inhibitor (acarbose), combined with a low-carbohydrate diet on the treatment of naturally occurring diabetes mellitus in cats. Eighteen client-owned cats with naturally occurring diabetes mellitus were entered into the study. Dual-energy X-ray absorptiometry (DEXA) was performed prior to and 4 months after feeding the diet to determine total body composition, including lean body mass (LBM) and percent body fat. Each cat was fed a commercially available low-carbohydrate canned feline diet and received 12.5mg/cat acarbose orally every 12h with meals. All cats received subcutaneous insulin therapy except one cat in the study group that received glipizide (5mg BID PO). Monthly serum glucose and fructosamine concentrations were obtained, and were used to adjust insulin doses based on individual cat's requirements. Patients were later classified as responders (insulin was discontinued, n=11) and non-responders (continued to require insulin or glipizide, n=7). Responders were initially obese (>28% body fat) and non-responders had significantly less body fat than responders (<28% body fat). Serum fructosamine and glucose concentrations decreased significantly in both responder and non-responder groups over the course of 4 months of therapy. Better results were observed in responder cats, for which exogenous insulin therapy was discontinued, glycemic parameters improved, and body fat decreased. In non-responders, median insulin requirements decreased and glycemic parameters improved significantly, despite continued insulin dependence. The use of a low-carbohydrate diet with acarbose was an effective means of decreasing exogenous insulin dependence and improving glycemic control in a series of client-owned cats with naturally occurring diabetes mellitus.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Mazzaferro
authors.forename: D S
authors.initials: DS
authors.lastname: Greco
authors.forename: A S
authors.initials: AS
authors.lastname: Turner
authors.forename: M J
authors.initials: MJ
authors.lastname: Fettman
mesh_terms: D015502:Absorptiometry, Photon / Q000662:veterinary; D020909:Acarbose / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose; D001823:Body Composition; D002371:Cat Diseases / Q000178:diet therapy* / Q000188:drug therapy*; D002415:Cats; D003920:Diabetes Mellitus / Q000178:diet therapy / Q000188:drug therapy / Q000662:veterinary*; D003927:Diet, Diabetic; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D005260:Female; D019270:Fructosamine / Q000097:blood; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D004040:Dietary Carbohydrates; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D019270:Fructosamine; D020909:Acarbose